California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
Solving Major Bottlenecks in Genetic Medicine and SynBio with DNA Synthesis Innovation
The Big4Bio Podcast
23 minutes 33 seconds
1 year ago
Solving Major Bottlenecks in Genetic Medicine and SynBio with DNA Synthesis Innovation
Despite significant advancements, the field of Synthetic Biology has yet to fully deliver on its promise of a world where we can overcome the challenges we face in human health and the environment by programming biology. Elegen has developed innovative, cell-free technologies that allow it to synthesize DNA with unprecedented speed, length, and quality. We spoke to Matt Hill, founder and CEO of Elegen, about Elegen’s ENFINIA DNA technology, the need it addresses, and how it has disrupted the status quo for DNA synthesis.
The Big4Bio Podcast
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
